沙丙蝶呤改善苯丙酮尿症患儿神经精神功能
这项随机双盲试验纳入86名8-17岁苯丙酮尿症患儿,沙丙蝶呤组43例、安慰剂组43例治疗13周后,沙丙蝶呤组血苯丙氨酸平均变化-20.9%、安慰剂组+2.9%,且注意缺陷多动障碍评定量表总分及注意缺陷、多动/冲动亚量表改善显著优于安慰剂。
要点
- 沙丙蝶呤治疗13周可降低苯丙酮尿症患儿血苯丙氨酸水平。
- 沙丙蝶呤组ADHD RS-IV总分、注意缺陷和多动/冲动亚量表评分改善显著优于安慰剂。
- 焦虑和抑郁评分两组无显著差异,沙丙蝶呤耐受性良好。
核心结论
- 沙丙蝶呤降低血苯丙氨酸,并与家长报告的注意缺陷、多动/冲动及执行功能症状显著改善相关。
研究设计与样本
- 8-17岁苯丙酮尿症患者86例随机分配至双盲沙丙蝶呤组43例或安慰剂组43例治疗13周,随后全部开放标签沙丙蝶呤治疗13周。
主要发现
- 13周随机化阶段后,沙丙蝶呤组和安慰剂组血苯丙氨酸平均变化分别为-20.9%和+2.9%。
- ADHD RS-IV总分最小二乘均数差异为-3.2分(P = .02),注意缺陷亚量表为-1.8分(P = .04),多动/冲动亚量表为-1.6分(P = .02),均显著利于沙丙蝶呤组。
- 森林图显示所有ADHD RS-IV和执行功能行为评定量表指数均倾向于沙丙蝶呤治疗优于安慰剂。
- 基线时及13周开放标签治疗后的第26周,两组报告注意或执行功能问题无显著差异。
- 焦虑和抑郁评分在任何时间点两组间均无显著差异,沙丙蝶呤耐受性良好且安全性良好。
临床怎么用
- 对于8-17岁苯丙酮尿症患儿,沙丙蝶呤可作为降低血苯丙氨酸并改善家长报告注意缺陷多动症状及执行功能的治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate effects of sapropterin dihydrochloride on blood phenylalanine (Phe) and symptoms of neuropsychiatric impairment in children and adolescents with phenylketonuria (PKU). STUDY DESIGN: PKU subjects 8-17 years of age (n = 86) were randomized to double-blind treatment with sapropterin (n = 43) or placebo (n = 43) for 13 weeks, then all received open-label sapropterin therapy for an additional 13 weeks. Blood Phe and symptoms of inattention, hyperactivity/impulsivity (Attention-Deficit/Hyperactivity Disorder Rating Scale IV [ADHD RS-IV]), executive functioning (Behavior Rating Inventory of Executive Function), depression (Hamilton Rating Scale for Depression), and anxiety (Hamilton Rating Scale for Anxiety) were assessed. RESULTS: Following the 13-week randomization phase, the sapropterin and placebo groups had mean changes in blood Phe of -20.9% and +2.9%, respectively. Corresponding least square mean differences in ADHD RS-IV scores were significantly greater for the sapropterin vs the placebo group: Total (-3.2 points, P = .02), Inattention subscale (-1.8 points, P = .04), and Hyperactivity/Impulsivity subscale (-1.6 points, P = .02). Forest plots favored sapropterin treatment over placebo for all ADHD RS-IV and Behavior Rating Inventory of Executive Function indices. There were no significant differences in reported problems with attention or executive function between the 2 groups at baseline or at week 26 following the 13-week open-label treatment period. Anxiety and depression scores did not differ significantly between cohorts at any time. Sapropterin was well tolerated, with a favorable safety profile. CONCLUSIONS: Sapropterin reduced blood Phe and was associated with significant improvement in parent-reported symptoms of inattention, hyperactivity/impulsivity, and executive functioning in children and adolescents with PKU. TRIAL REGISTRATION: ClinicalTrials.gov, NCT01114737. Registered 27 April 2010, https://clinicaltrials.gov/ct2/show/NCT01114737.
引用
- Grant ML, Jurecki ER, McCandless SE, et al. Neuropsychiatric Function Improvement in Pediatric Patients with Phenylketonuria. J Pediatr. 2023. PMID: 37263523. doi:10.1016/j.jpeds.2023.113526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。